1.

Record Nr.

UNISA996206561303316

Titolo

1996 1st International Symposium on Plasma Process-Induced Damage : 13-14 May 1996, Santa Clara, California, USA

Pubbl/distr/stampa

[Place of publication not identified], : Northern California Chapter of the American Vacuum Society, 1996

Disciplina

621.3815/2

Soggetti

Semiconductor wafers - Congresses

Semiconductors - Congresses - Effect of radiation on

Plasma radiation - Congresses

Electrical & Computer Engineering

Electrical Engineering

Engineering & Applied Sciences

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Bibliographic Level Mode of Issuance: Monograph



2.

Record Nr.

UNINA9910962297103321

Autore

Rees Hedley

Titolo

Supply chain management in the drug industry : delivering patient value for pharmaceuticals and biologics / / Hedley Rees

Pubbl/distr/stampa

Hoboken, NJ, : Wiley, c2011

ISBN

9786613025449

9780470922842

0470922842

9781283025447

1283025442

9780470920817

0470920815

9780470920534

047092053X

Edizione

[1st ed.]

Descrizione fisica

1 online resource (458 p.)

Disciplina

615.1068/5

Soggetti

Pharmaceutical industry - Materials management

Business logistics

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Includes index.

Nota di contenuto

SUPPLY CHAIN MANAGEMENT IN THE DRUG INDUSTRY; CONTENTS; CONTRIBUTORS; PREFACE; I SURVEYING AND MAPPING THE TERRITORY; II BUILDING A KNOWLEDGE FOUNDATION IN SCM; III PLANNING AND EXECUTING SUPPLY CHAIN CHANGE; END NOTES; INDEX

Sommario/riassunto

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should star